Market Place
Sourcing Support
Nuvectis Pharma Reports Positive NXP800 Data in Ovarian Cancer
14 Nov 2024 //
GLOBENEWSWIRE
Nuvectis Pharma Reports Q3 2024 Financial Results & Business
05 Nov 2024 //
GLOBENEWSWIRE
Nuvectis Pharma`s NXP900 Shows Promising Synergy in Presentations
28 Oct 2024 //
BUSINESSWIRE
Nuvectis To Participate In 3rd Annual ROTH Healthcare Conference
07 Oct 2024 //
GLOBENEWSWIRE
PESG Reports On Nuvectis Pharma`s NXP900
16 Sep 2024 //
BUSINESSWIRE
Nuvectis To Present At H.C. Wainwright Investment Conference
05 Sep 2024 //
GLOBENEWSWIRE
Nuvectis Pharma Gets Orphan Drug Status for NXP800 in ARID1a-Deficient Cancers
29 Aug 2024 //
GLOBENEWSWIRE
Nuvectis Pharma Reports Q2 2024 Results And Business Highlights
06 Aug 2024 //
GLOBENEWSWIRE
Nuvectis Pharma To Present At Wainwright BioConnect
16 May 2024 //
GLOBENEWSWIRE
Nuvectis Pharma Reports Q1 2024 Financials And Business Highlights
07 May 2024 //
GLOBENEWSWIRE
Nuvectis NXP900 Demonstrates Activity in NSCLC
08 Apr 2024 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Upcoming Presentations at the 2024
19 Mar 2024 //
GLOBENEWSWIRE
Nuvectis Pharma to Present at the 36th Annual Roth Conference
15 Mar 2024 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800
14 Mar 2024 //
GLOBENEWSWIRE
Nuvectis Reports Fiscal Year 2023 Financial Results and Business Highlights
05 Mar 2024 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
09 Feb 2024 //
GLOBENEWSWIRE
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Nuvectis Pharma Announces a Collaboration with Mayo Clinic to Evaluate NXP800
18 Dec 2023 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800
24 Oct 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Conference
25 Sep 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
21 Sep 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
12 Sep 2023 //
GLOBENEWSWIRE
Nuvectis Pharma to Host KOL Event to Discuss Drug Candidates, NXP800 and NXP900
06 Sep 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
01 Sep 2023 //
GLOBENEWSWIRE
Nuvectis Announces Orphan Drug Designation Granted by the FDA to NXP800
17 Aug 2023 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
20 Jun 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
15 May 2023 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. Reports 1Q 2023 Financial Results and Business Highlights
10 May 2023 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect
27 Apr 2023 //
GLOBENEWSWIRE
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
27 Apr 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800`s Activity
18 Apr 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800
10 Apr 2023 //
GLOBENEWSWIRE
Nuvectis Announces Presentations at American Association for Cancer Meeting
17 Mar 2023 //
GLOBENEWSWIRE
Nuvectis to Participate in a Fireside Chat at the 35th Annual Roth Conference
10 Mar 2023 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800
23 Feb 2023 //
GLOBENEWSWIRE
Nuvectis Announce Publication in The Journal of Experimental Medicine for NXP900
09 Feb 2023 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation
04 Jan 2023 //
GLOBENEWSWIRE
FDA Grants Fast Track Designation to Nuvectis Pharma`s NXP800
01 Dec 2022 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. Reports3Q 2022 Financial Results and Business Highlights
08 Nov 2022 //
GLOBENEWSWIRE
Nuvectis Phrama Announces Poster Presentations at EORTC-NCI-AACR Symposium
18 Oct 2022 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities
03 Oct 2022 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
28 Sep 2022 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model
13 Sep 2022 //
GLOBENEWSWIRE
Nuvectis Pharma Reports Second Quarter 2022 Financial Results
05 Aug 2022 //
GLOBENEWSWIRE
Nuvectis Pharma Announces Closing of Approximately $15.9M Private Placement
01 Aug 2022 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
27 Jul 2022 //
GLOBENEWSWIRE
Nuvectis Pharma Announces FDA Clearance of IND for NXP800
21 Jun 2022 //
GLOBENEWSWIRE
The stock price of Nuvectis Pharma increased by over 3% during intraday
13 Jun 2022 //
PULSE2
Nuvectis Pharma Announces Positive Data for NXP900 in Group 4 Medulloblastoma
13 Jun 2022 //
GLOBENEWSWIRE
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
20 May 2022 //
GLOBENEWSWIRE
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at 2022 AACR
13 Apr 2022 //
GLOBENEWSWIRE
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at AACR
11 Apr 2022 //
GLOBENEWSWIRE
Nuvectis Pharma Reports Fiscal Year 2021 Financial Results
22 Mar 2022 //
GLOBENEWSWIRE
Nuvectis says Upcoming Oral and Poster Presentations at the 2022 AACR Meeting
10 Mar 2022 //
GLOBENEWSWIRE
Nuvectis Pharma to Participate in Fireside Chat at 34th Annual Roth Conference
09 Mar 2022 //
GLOBENEWSWIRE
Nuvectis Announces Positive Data for NXP900 in TNBC Pre-clinical Model
22 Feb 2022 //
PRESS RELEASE
